Gilead Warns After Hepatitis Patient on Heart Drug Dies - (Bloomberg via NewsPoints Desk)

  • Gilead Sciences said nine patients taking the heart drug amiodarone co-administered with either of its hepatitis C drugs, Harvoni or Sovaldi, developed bradycardia and one died of cardiac arrest, while three required a pacemaker, reported Bloomberg.
  • The company stated that six cases of symptomatic bradycardia occurred within the first 24 hours of treatment and the remaining three within the first two to 12 days.
  • Specifically, the news source said the patients were all taking amiodarone, with three also using Harvoni, five receiving Sovaldi in combination with Bristol-Myers Squibb's daclatasvir and one on Sovaldi plus Johnson & Johnson's Olysio.
  • Gilead said the combinations are not recommended and that it will update its product labeling.
  • Harvoni generated $2.1 billion in sales in the fourth quarter of 2014, while Sovaldi brought in $1.7 billion.

To read more NewsPoints articles, click here.